UNSPSC 51292013: Fluvoxamine

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O4L1XPO44W. European Medicines Agency schedules Fluvoxamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07769MIG. Fluvoxamine generally arises in the molecular formula C15H21F3N2O2.

UNSPSC 51292013 Fluvoxamine, a Commodity code, nominally covers a single psychiatric medication, but state and local procurement activity tagged to this code reflects a far broader pattern of pharmaceutical and health-supply acquisitions. Recent opportunities show county health departments and state agencies sourcing generic pharmaceuticals, naloxone and drug deactivation systems, and over-the-counter products through competitive bidding and cooperative purchasing arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota, Oregon, and participating jurisdictions). Work solicited ranges from annual commodity purchases of naloxone and related harm-reduction supplies to statewide or multistate framework agreements for generic pharmaceuticals and OTC products supplied through authorized wholesale channels.

Activity clusters in Florida, Texas, and the Upper Midwest (Minnesota and Oregon). Representative recent opportunities include Seminole County, Florida's IFB60459723LAS, an IFB posted June 30, 2026, with response due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, exploring direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, with response due March 26, 2026, establishing multistate framework agreements for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with awarded vendors effective July 1, 2026.